{"Clinical Trial ID": "NCT00572728", "Intervention": ["INTERVENTION 1:", "Diagnosis (18F-FLT)", "Patients undergo baseline PET/CT 18F-FLT (before chemotherapy, FLT-1), early treatment (5-10 days after the start of the first cycle of chemotherapy, FLT-2) and post-treatment treatment (within 3 weeks prior to surgery, FLT-3).", "Fluorothymidine F-18: less than 18F-FLT PET/CT", "positron emission tomography: 18F-FLT PET/CT captioning", "Undergo 18F-FLT PET/CT", "Analysis of laboratory biomarkers: related studies"], "Eligibility": ["Incorporation criteria:", "A pathologically confirmed breast cancer, determined as a candidate for systemic primary treatment (neoadjuvant) and surgical resection of the residual primary tumour after completion of neoadjuvant treatment", "A locally advanced breast cancer, not stage IV, and with a tumour size >= 2 cm (measured on imaging or estimated by physical examination)", "No obvious contraindications for primary chemotherapy", "\u2022 Residual tumour is expected to be surgically eliminated after completion of neoadjuvant treatment", "\u2022 Capable of remaining stationary for 1.5 hours for PET scanning", "= < 2 (Karnofsky >= 60%)", "Leukocytes >= 3000/ul", "Absolute number of neutrophils >= 1,500/ul", "Platelets >= 100 000/ul", "Total bilirubin within normal institutional limits", "Aspartate aminotransferase (AST) (oxaloacetic glutamic serum transaminase [SGOT])/alanine aminotransferase (ALT) (s\u00e9r\u00e9m glutamate pyruvate transaminase [SGPT]) = < 2.5 times the upper institutional limit of normal", "\u2022 Creatinine within normal institutional limits OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal", "In the case of a woman who is menopausal for at least one year, OR surgically sterile, or unpregnant, confirmed by an institutional pregnancy test (SOC) and willing to use adequate contraception (hormonal method or contraceptive barrier; abstinence) during the duration of the study", "Able to understand and wish to sign a written informed consent document and an authorization from the Health Insurance Portability and Liability Act (HISA) in accordance with institutional guidelines", "- Exclusion criteria:", "Previous treatment (chemotherapy, radiotherapy or surgery) in the breast involved; including hormone therapy", "\u2022 Uncontrolled intercurrent disease including, but not limited to, continuous or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia or psychiatric or social conditions that would limit compliance with study requirements", "From a medical point of view, instability", "\u2022 Condition requiring anaesthesia for PET scanning and/or unable to remain stationary for 1.5 hours", "History of allergic reactions attributed to compounds of chemical or biological composition similar to F-18 fluorthymidine", "\u2014 Pregnant or lactating", "A prior malignancy, other than basal cell or squamous carcinoma of the skin or in situ cervix carcinoma of the cervix, of which the patient has been free for less than 5 years", "Currently, hormone therapy is the main neoadjuvant systemic therapy"], "Results": ["Performance measures:", "Percentage variation in ALT intake between baseline (pre-therapy) and early imaging studies to predict complete pathological response", "The primary statistical assessment will be based on the percentage variation of the SUV60 FLT between initial studies (pre-therapy, FLT-1) and early imaging studies (5-10 days after chemotherapy, FLT-2)", "Timeline: reference (FLT-1) to early treatment (5-10 days after chemotherapy, FLT-2)", "Results 1:", "Title of the arm/group: Diagnostic (18F-FLT)", "Patients undergo baseline 18F-FLT TEP/CT (before chemotherapy, FLT-1), early treatment (5-10 days after the start of the first cycle of chemotherapy, FLT-2) and post-treatment (within 3 weeks prior to surgery, FLT-3). Patients undergo a standard surgical resection of the residual tumour after the completion of neoadjuvant chemotherapy.", "Fluorothymidine F-18: less than 18F-FLT PET/CT", "positron emission tomography: 18F-FLT PET/CT captioning", "Undergo 18F-FLT PET/CT", "Analysis of laboratory biomarkers: related studies", "Total number of participants analysed: 51", "Average (standard deviation)", "Unit of measurement: percentage change of SUVmax 38.78 (26.07)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/90 (0.00 per cent)"]}